Top

31-03-2018 | Psoriatic arthritis | Article

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison

Journal: Rheumatology and Therapy

Authors: Peter Nash, Iain B. McInnes, Philip J. Mease, Howard Thom, Matthias Hunger, Andreas Karabis, Kunal Gandhi, Shephard Mpofu, Steffen M. Jugl

Publisher: Springer Healthcare

Abstract

Introduction

Secukinumab and adalimumab are approved for adults with active psoriatic arthritis (PsA). In the absence of direct randomized controlled trial (RCT) data, matching-adjusted indirect comparison can estimate the comparative effectiveness in anti-tumor necrosis factor (TNF)-naïve populations.

Methods

Individual patient data from the FUTURE 2 RCT (secukinumab vs. placebo; N = 299) were adjusted to match baseline characteristics of the ADEPT RCT (adalimumab vs. placebo; N = 313). Logistic regression determined adjustment weights for age, body weight, sex, race, methotrexate use, psoriasis affecting ≥ 3% of body surface area, Psoriasis Area and Severity Index score, Health Assessment Questionnaire Disability Index score, presence of dactylitis and enthesitis, and previous anti-TNF therapy. Recalculated secukinumab outcomes were compared with adalimumab outcomes at weeks 12 (placebo-adjusted), 16, 24, and 48 (nonplacebo-adjusted).

Results

After matching, the effective sample size for FUTURE 2 was 101. Week 12 American College of Rheumatology (ACR) response rates were not significantly different between secukinumab and adalimumab. Week 16 ACR 20 and 50 response rates were higher for secukinumab 150 mg than for adalimumab (P = 0.017, P = 0.033), as was ACR 50 for secukinumab 300 mg (P = 0.030). Week 24 ACR 20 and 50 were higher for secukinumab 150 mg than for adalimumab (P = 0.001, P = 0.019), as was ACR 20 for secukinumab 300 mg (P = 0.048). Week 48 ACR 20 was higher for secukinumab 150 and 300 mg than for adalimumab (P = 0.002, P = 0.027), as was ACR 50 for secukinumab 300 mg (P = 0.032).

Conclusions

In our analysis, patients with PsA receiving secukinumab were more likely to achieve higher ACR responses through 1 year (weeks 16–48) than those treated with adalimumab. Although informative, these observations rely on a subgroup of patients from FUTURE 2 and thus should be considered interim until the ongoing head-to-head RCT EXCEED can validate these findings.

Funding

Novartis Pharma AG.

Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510.CrossRefPubMed

Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012;71(1):4–12.CrossRefPubMed

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–71.PubMed

Tintle SJ, Gottlieb AB. Psoriatic arthritis for the dermatologist. Dermatol Clin. 2015;33(1):127–48.CrossRefPubMed

NCT02745080. Efficacy of secukinumab compared to adalimumab in patients with psoriatic arthritis (EXCEED 1). 2016. https://clinicaltrials.gov/ct2/show/NCT02745080. Accessed 1 Dec 2017.

Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-analysis of randomized controlled trials. Med Decis Making. 2013;33(5):607–17.CrossRefPubMedPubMedCentral

Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91.CrossRefPubMed

Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–7.CrossRefPubMed

Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submission to NICE. 2016. http://www.nicedsu.org.uk. Accessed 1 Dec 2017.

10.

Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200–11.

11.

Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935–45.CrossRefPubMed

12.

Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A. Comparative effectiveness of adalimumab versus secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison. Rheumatol Ther. 2017;4(2):349–62.CrossRefPubMedPubMedCentral

13.

Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M. Matching-adjusted indirect comparison of adalimumab vs. etanercept and infliximab for the treatment of psoriatic arthritis. J Med Econ. 2013;16(4):479–89.CrossRefPubMed

14.

Thom H, Jugl SM, Palaka E, Jawla S. Matching adjusted indirect comparisons to assess comparative effectiveness of therapies: usage in scientific literature and health technology appraisals. Value Health. 2016;19:A100–1.CrossRef

15.

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52(10):3279–89.CrossRefPubMed

16.

Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56(2):476–88.CrossRefPubMed

17.

Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis. 2009;68(5):702–9.CrossRefPubMed

18.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;386(9999):1137–46.CrossRefPubMed

19.

Armuzzi A, Lionetti P, Blandizzi C, Caporali R, Chimenti S, Cimino L, et al. Anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab. Int J Immunopathol Pharmacol. 2014;27(1 Suppl):11–32.CrossRefPubMed

20.

Thaci D, Blauvelt A, Reich K, Tsai TF, Vanaclocha F, Kingo K, et al. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am Acad Dermatol. 2015;73(3):400–9.CrossRefPubMed

21.

Langley RG, Elewski BE, Lebwohl M, Reich K, Griffiths CE, Papp K, et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med. 2014;371(4):326–38.CrossRefPubMed

22.

Mease PJ, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab inhibition of interleukin-17A in patients with psoriatic arthritis. N Engl J Med. 2015;373(14):1329–39.CrossRefPubMed

23.

McInnes IB, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs JD, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73(2):349–56.CrossRefPubMed

24.

Behrens F, Kohm M, Arndt U, Wittig B, Greger G, Thaci D, et al. Impact of methotrexate on anti-TNF treatment in psoriatic arthritis? An in-depth analysis of a large prospective observational study with adalimumab. Ann Rheum Dis. 2014;73:723.CrossRef

25.

Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol. 2007;34(5):1040–50.PubMed

26.

van Kuijk AW, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2009;68(8):1303–9.CrossRefPubMed

27.

McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, et al. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. Rheumatology. 2017;56(11):1993–2003.CrossRefPubMedPubMedCentral

28.

Kavanaugh A, McInnes IB, Mease PJ, Hall S, Chinoy H, Kivitz AJ, et al. Efficacy of subcutaneous secukinumab in patients with active psoriatic arthritis stratified by prior tumor necrosis factor inhibitor use: results from the randomized placebo-controlled FUTURE 2 study. J Rheumatol. 2016;43(9):1713–7.CrossRefPubMed

29.

Mease P, McInnes IB. Secukinumab: a new treatment option for psoriatic arthritis. Rheumatol Ther. 2016;3(1):5–29.CrossRefPubMedPubMedCentral

30.

Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–35.CrossRefPubMed

31.

Gladman DD, Investigators AS, Sampalis JS, Illouz O, Guerette B. Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. J Rheumatol. 2010;37(9):1898–906.CrossRefPubMed

32.

Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, et al. Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. Exp Hematol Oncol. 2013;2(1):32.CrossRefPubMedPubMedCentral

33.

Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007;34(5):1167–70.PubMed

34.

Tillett W, Eder L, Goel N, De Wit M, Gladman DD, FitzGerald O, et al. Enhanced patient involvement and the need to revise the core set—report from the Psoriatic Arthritis Working Group at OMERACT 2014. J Rheumatol. 2015;42(11):2198–203.CrossRefPubMed

35.

Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, et al. Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. J Rheumatol. 2016;43(5):965–9.CrossRefPubMedPubMedCentral

36.

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46(3):399–424.CrossRef

37.

Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, et al. Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. J Comp Eff Res. 2016;5(2):129–39.

38.

Dearden L, Majer I, Heeg B, Liwing J, Sandstrom K, Diels J. Comparison of mean overall survival (OS) and radiographic progression free survival (RPFS) based on matching adjusted indirect comparison of abiraterone acetate and enzalutamide for the treatment of castration-resistant prostate cancer in chemotherapy naive patients. Value Health. 2014;17(7):A616.CrossRefPubMed

39.

Wasserstein RL, Lazar NA. The ASA’s statement on p-values: context, process, and purpose. Am Stat. 2016;70(2):129–33.CrossRef

40.

Best AM 3rd, Greenberg BL, Glick M. From tea tasting to t test: a P value ain’t what you think it is. J Am Dent Assoc. 2016;147(7):527–9.CrossRefPubMed

41.

Sterne JA, Davey Smith G. Sifting the evidence—what’s wrong with significance tests? BMJ. 2001;322(7280):226–31.CrossRefPubMedPubMedCentral

42.

Goodman S, Greenland S. Why most published research findings are false: problems in the analysis. PLoS Med. 2007;4(4):e168.CrossRefPubMedPubMedCentral

43.

Kang EJ, Kavanaugh A. Psoriatic arthritis: latest treatments and their place in therapy. Ther Adv Chronic Dis. 2015;6(4):194–203.CrossRefPubMedPubMedCentral

44.

Behrens F, Canete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B. Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology. 2015;54(5):915–26.CrossRefPubMed

45.

Zisapel M, Zisman D, Madar-Balakirski N, Arad U, Padova H, Matz H, et al. Prevalence of TNF-alpha blocker immunogenicity in psoriatic arthritis. J Rheumatol. 2015;42(1):73–8.CrossRefPubMed

46.

van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis. 2010;69(3):624–5.CrossRefPubMed

47.

Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014;73(9):1689–94.CrossRefPubMedPubMedCentral

48.

Murdaca G, Spano F, Contatore M, Guastalla A, Penza E, Magnani O, et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety? Expert Opin Drug Saf. 2016;15(1):43–52.CrossRefPubMed

49.

Mease PJ, Collier DH, Saunders KC, Li G, Kremer JM, Greenberg JD. Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry. RMD Open. 2015;1(1):e000181.CrossRefPubMedPubMedCentral

50.

Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, et al. Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology. CNS Drugs. 2013;27(11):943–53.CrossRefPubMedPubMedCentral

51.

Veroniki AA, Straus SE, Soobiah C, Elliott MJ, Tricco AC. A scoping review of indirect comparison methods and applications using individual patient data. BMC Med Res Methodol. 2016;16(1):47.CrossRefPubMedPubMedCentral

52.

Ceponis A, Kavanaugh A. Treatment of psoriatic arthritis with biological agents. Semin Cutan Med Surg. 2010;29(1):56–62.CrossRefPubMed

53.

Saber TP, Veale DJ. Psoriatic arthritis management update—biotherapeutic options. J Rheumatol Suppl. 2009;83:65–8.CrossRefPubMed

54.

Ash Z, Gaujoux-Viala C, Gossec L, Hensor EM, FitzGerald O, Winthrop K, et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2012;71(3):319–26.CrossRefPubMed

55.

Sritheran D, Leung YY. Making the next steps in psoriatic arthritis management: current status and future directions. Ther Adv Musculoskelet Dis. 2015;7(5):173–86.CrossRefPubMedPubMedCentral

56.

Mease PJ. Psoriatic arthritis—update on pathophysiology, assessment, and management. Bull NYU Hosp Jt Dis. 2010;68(3):191–8.PubMed

57.

Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35(5):883–90.PubMed

58.

Lemos LL, de Oliveira Costa J, Almeida AM, Junior HO, Barbosa MM, Kakehasi AM, et al. Treatment of psoriatic arthritis with anti-TNF agents: a systematic review and meta-analysis of efficacy, effectiveness and safety. Rheumatol Int. 2014;34(10):1345–60.CrossRefPubMed

59.

National Institute for Health and Care Excellence: TA199, etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis. 2016. https://www.nice.org.uk/guidance/ta199. Accessed 1 Dec 2017.

60.

Fenix-Caballero S, Alegre-del Rey EJ, Castano-Lara R, Puigventos-Latorre F, Borrero-Rubio JM, Lopez-Vallejo JF. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther. 2013;38(4):286–93.CrossRefPubMed

61.

Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76(4):673–80.

62.

63.

Song F, Loke YK, Walsh T, Glenny AM, Eastwood AJ, Altman DG. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ. 2009;338:b1147.CrossRefPubMedPubMedCentral

64.

Kammüller M, Tsai TF, Griffiths CE, Kapoor N, Kolattukudy PE, Brees D, et al. Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections. Clin Transl Immunol. 2017;6:e152.CrossRef

65.

Gladman DD, Mease PJ, Cifaldi MA, Perdok RJ, Sasso E, Medich J. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the adalimumab effectiveness in psoriatic arthritis trial. Ann Rheum Dis. 2007;66(2):163–8.CrossRefPubMed

66.

Gottlieb AB, Langley RG, Philipp S, Sigurgeirsson B, Blauvelt A, Martin R, et al. Secukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trials. J Drugs Dermatol. 2015;14(8):821–33.PubMed

67.

Gottlieb AB, Sigurgeirsson B, Blauvelt A, Mpfofu S, Martin R, Papavassilis C. Secukinumab shows substantial improvement in both psoriasis symptoms and physical functioning in moderate-to-severe plaque psoriasis patients with psoriatic arthritis: a subanalysis of a phase 3, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 2013;65:S136–7.

68.

Blauvelt A, Gottlieb A, Sigurgeirsson B, Papavassilis C, Martin R. Secukinumab efficacy in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a subanalysis of the ERASURE study. J Am Acad Dermatol. 2014;70(5):AB2.

69.

Gottlieb A, Sigurgeirsson B, Blauvelt A, Gong Y, Papavassilis C, Mpofu S. Secukinumab reduces hsCRP levels in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a sub-analysis from the phase 3 erasure study. Ann Rheum Dis. 2014;73:1047–8.CrossRef

70.

Philipp S, Gottlieb AB, Langley RG, Sigurgeirsson B, Blauvelt A, Gong Y, et al. Secukinumab decreases inflammation as measured by a biomarker hsCRP in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: subanalyses from two phase 3 studies. Exp Dermatol. 2015;24(3):E27.

71.

Gottlieb A, Langley R, Philipp S, Martin R, Papavassilis C, Mpfofu S. Improvement in psoriasis symptoms and physical functioning with secukinumab compared with placebo and etanercept in subjects with moderate-to-severe plaque psoriasis and psoriatic arthritis: results of a subanalysis from the phase 3 fixture study. Arthritis Rheum. 2013;65(12):3322.

72.

Sigurgeirsson B, Gottlieb AB, Langley RG, Philipp S, Martin RLM, Papavassilis C, et al. Effect of secukinumab on psoriasis symptoms and physical functioning compared with placebo and etanercept in subjects with moderate-to-severe plaque psoriasis and concomitant psoriatic arthritis: a subanalysis from the phase 3 fixture study. Scand J Rheumatol. 2014;43:64–5.

73.

Gottlieb AB, Mease P, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial. Arthritis Rheum. 2014;66(Suppl 10):S233.

74.

Mease P, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, van der Heijde D, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 2014;66(Suppl 10):S423–4.

75.

Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, Van der Heijde D, et al. Secukinumab provides sustained improvements in psoriatic arthritis: 2-year efficacy and safety results from a phase 3 randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2015;67(Suppl 10):2576–8.

76.

Mease P, McInnes I, Kirkham B, Kavanaugh A, Rahman P, Van der Heijde D, et al. Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study. J Invest Dermatol. 2015;135:S29.

77.

Strand V, Mease P, McInnes IB, Kirkham B, Kavanaugh A, Rahman P, et al. Secukinumab, an anti-interleukin-17A monoclonal antibody, improves physical function, quality of life and work productivity in patients with active psoriatic arthritis: results from a phase 3, randomized, controlled trial. Arthritis Rheumatol. 2014;66(Suppl 10):S240–1.

78.

van der Heijde D, Landewe RBM, Mease P, McInnes IB, Conaghan PG, Pricop L, et al. Secukinumab, a monoclonal antibody to interleukin-17A, provides significant and sustained inhibition of joint structural damage in active psoriatic arthritis regardless of prior TNF inhibitors or concomitant methotrexate: a phase 3 randomized, double-blind, placebo-controlled study. Arthritis Rheumatol. 2014;66:S424–5.CrossRef

79.

Gottlieb A, McInnes I, Mease P, Kirkham B, Kavanaugh A, Ligozio G, et al. Secukinumab improves signs and symptoms of active psoriatic arthritis: results from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using a subcutaneous dosing regimen (FUTURE 2). J Invest Dermatol. 2015;135(Suppl 3):S29.

80.

Gottlieb A, Strand V, McInnes I, Marzo-Ortega H, Kavanaugh A, Kandala S, et al. Secukinumab improves physical function, quality of life, fatigue and work productivity in patients with active psoriatic arthritis: results of a randomized, double-blind, placebo-controlled phase 3 trial (FUTURE 2). J Invest Dermatol. 2015;135:S30.

81.

Kavanaugh A, McInnes I, Mease P, Hall S, Chinoy H, Kivitz AJ, et al. Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis in anti-TNF-naive patients and those previously exposed to anti-TNF therapy: 52-week results from a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous dosing. Arthritis Rheumatol. 2015;67(Suppl 10):2890.

82.

McInnes IB, Mease PJ, Kirkham B, Kavanaugh A, Ritchlin CT, Rahman P, et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis: 24-week efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using subcutaneous dosing. Arthritis Rheumatol. 2014;66(Suppl 10):3529.

83.

Mease P, Kirkham B, McInnes I, Kremer J, Kandala S, Pricop L, et al. Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 2). J Invest Dermatol. 2015;135(Suppl 3):S30.

84.

Rahman P, Strand V, McInnes I, Marzo-Ortega H, Dokoupilova E, Churchill M, et al. Secukinumab improves physical function, quality of life, fatigue and work productivity in patients with active psoriatic arthritis in FUTURE 2, a phase 3 trial. Ann Rheum Dis. 2015;74(Suppl 2):356.CrossRef

85.

Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease-modifying antirheumatic drug therapy. J Rheumatol. 2007;34:1040–50.PubMed

86.

McInnes I, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs J, et al. Secukinumab, a fully human anti-interleukin-17A antibody, improves signs and symptoms of psoriatic arthritis: a 24-week, double-blind, placebo-controlled, multicenter trial. Dermatol Ther. 2012;2:S37.

87.

McInnes I, Sieper J, Braun J, Emery P, van der Heijde D, Isaacs J, et al. Effect of secukinumab on signs and symptoms of psoriatic arthritis: results of a 24-week multicentre, double-blind, randomized, placebo-controlled trial. Rheumatology (United Kingdom). 2012;51:iii90–1.

88.

de Groot M, Picavet DI, van Kuijk AW, Tak PP, Bos JD, de Rie MA, et al. A prospective, randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin. Dermatology. 2012;225(4):298–303.CrossRefPubMed